Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea [0.03%]
Teclistamab治疗韩国复发/难治多发性骨髓瘤患者的现实世界疗效和安全性：命名患者项目的全国回顾性分析
Jun Ho Yi,Jae Hoon Lee,Sung-Hoon Jung et al.
Jun Ho Yi et al.
Purpose: The prognosis for heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) remains poor. Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, has demonstra...
BTG1 Mutation Correlates with Inferior Prognosis in Diffuse Large B-Cell Lymphoma [0.03%]
BTG1突变与弥漫性大B细胞淋巴瘤不良预后相关
Chun-Yu Shang,Wei Hua,Tong-Yao Xing et al.
Chun-Yu Shang et al.
Purpose: B celltranslocation gene 1 (BTG1) is a highly conserved gene and recurrently mutated in the MCD subtype of diffuse large B-cell lymphoma (DLBCL). The specific enrichment of BTG1 mutation (BTG1mut) raises a potentia...
Microbial Dynamics Across Molecular Subtypes and Prognostic Significance of Lactobacillus in Gastric Cancer [0.03%]
分子亚型之间的微生物动力学及乳杆菌在胃癌预后中的意义
Soo Kyung Nam,Juhyeong Park,Sujin Oh et al.
Soo Kyung Nam et al.
Purpose: Recent studies have revealed a diverse gastric microbiota beyond Helicobacter pylori, suggesting a role in gastric cancer (GC). We aimed to investigate the composition and characteristics of the microbiota in GC ...
Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function [0.03%]
基于基线肝功能的免疫检查点抑制剂相关性肝毒性的特征分析
Won-Jung Jung,Eun-Jung Jo,Ye-Jee Kim et al.
Won-Jung Jung et al.
Purpose: This study estimated the incidence of immune checkpoint inhibitor-related hepatotoxicity (ICH), identified risk factors, and characterized patients who developed ICH. ...
Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [0.03%]
与Tisagenlecleucel相比，Anbalcabtagene autoleucel治疗复发/难治性弥漫大B细胞淋巴瘤的有效性如何？
Hee-Jin Seo,Woo Hyeon Yoo,Kyungyeon Jung et al.
Hee-Jin Seo et al.
Purpose: Anbalcabtagene autoleucel (anbal-cel) is a second-generation CD19-targeted chimeric antigen receptor-T cell therapy reducing T-cell exhaustion through PD-1 and TIGIT downregulation. We compared efficacy of anbal-...
Keratin 6A Overexpression in the Lymphovascular Invasion-Associated Tumor Subgroup Promotes Progression of Triple-Negative Breast Cancer [0.03%]
角蛋白6A在淋巴管浸润相关肿瘤亚群中的过表达促进三阴性乳腺癌进展
Wei Luo,Yiping Zou,Yantao Jiang et al.
Wei Luo et al.
Purpose: Lymphovascular invasion (LVI) is a strong predictor of poor prognosis in triple-negative breast cancer (TNBC), yet its molecular basis remains unclear. This study investigates epithelial regulators associated wit...
Barriers to Clinical Trial Enrollment: KCSG Survey-Based Perspectives of Medical Oncologists, Patients, and Their Caregivers [0.03%]
韩国血液肿瘤医师、患者及照料者关于临床试验入组障碍的调查结果
Chi Hoon Maeng,Inkeun Park,In Hee Lee et al.
Chi Hoon Maeng et al.
Purpose: Despite the critical role of clinical trials in advancing cancer treatment, patient enrollment remains challenging in South Korea. We aimed to identify key barriers to clinical trial participation from the perspe...
Impact of High Lymph Node Burden on Brain Metastases in Patients Who Achieved Pathological Complete Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer [0.03%]
新辅助化疗后HER2阳性乳腺癌病理完全缓解患者的高淋巴结负荷对脑转移影响的研究
Seung Ah Lee,Ki Jo Kim,Do Youn Woen et al.
Seung Ah Lee et al.
Purpose: This study aims to investigate the clinical characteristics, outcomes, and predictors of brain metastases in HER2-positive advanced breast cancer patients who achieved pathological complete response (pCR) followi...
A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906) [0.03%]
达雷妥尤单抗联合硼替佐米和地塞米松治疗接受过一线治疗的多发性骨髓瘤患者的II期研究(KMM1906)
Kwai Han Yoo,Sang Eun Yoon,Ka-Won Kang et al.
Kwai Han Yoo et al.
Purpose: Daratumumab combined with bortezomib and dexamethasone (DVd) has been established as the standard treatment for relapsed/refractory multiple myeloma (MM) based on pivotal phase 3 trials. A subgroup analysis demon...
Detection of HIV RNA after CAR-T Cell Therapy in A Relapsed/refractory Diffuse Large B-cell Lymphoma Patient: Possibility of False Positivity and Clinical Implications [0.03%]
CAR-T细胞治疗后复发/难治性弥漫大B细胞淋巴瘤患者的HIV RNA检测阳性：假阳性的可能性及临床意义
Sang Eun Yoon,Kyungmin Huh,Tae Yeul Kim et al.
Sang Eun Yoon et al.
CAR-T cell therapy using lentiviral vectors can lead to false-positive HIV RNA detection, making distinguishing true infection from vector-related signals challenging. A 64-year-old male with relapsed/refractory DLBCL (RR-DLBCL) underwent m...
Case Reports
Cancer research and treatment. 2025 Jun 30. DOI:10.4143/crt.2025.491 2025